Project Number 2R44AG053150-05 Agency/Funding Organization NIA Funding Year 2020 View Full Project Details for Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD Research Categorization Primary Disease / Condition Alzheimer's Disease Frontotemporal Dementia CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) b. Tau Researcher and Organization Principal Investigator MOE, JAMES G Principal Investigator First Name JAMES Principal Investigator Last Name MOE Awardee Organization OLIGOMERIX, INC Awardee State New York, N.Y. Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-19-333: SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed FY Overall Cost $1,452,237 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official MARTIN, ZANE
